SinoVac/SinoPharm Covid-19 Vaccine

SinoVac Covid-19 Vaccine is making preparation to run production in China. se 3 Clinical Trial is ongoing and almost completion. These countries include China, Indonesia, Brazil and Turkey.

The se Ill clinical trial to assess efficacy and safety of the Adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac in health care professionals.Â

The study will be double-blind placebo-controlled trial with participants randomly allocated 1: 1 to placebo and vaccine arms.Â

The immunization schedule is two doses intramuscular injections (deltoid) with a 14-days interval.Â

For efficacy, the study aims to detect COVID-19 cases, defined as symptomatic SARS-CoV-2 infections, after the second week post-immunization schedule.Â

For safety and immunogenicity, participants are categorized in two age groups, Adults (18-59 years) and Elderly (60 years and above). Safety database aims to detect adverse reactions with frequency of 1: 1000 or higher in adults and 1 :500 in elderly.Â

All participants will be followed up to 12 months. Interim preliminary efficacy analysis can be triggered by reaching the target of 150 cases.Â